Tebipenem tablet form
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability
Trial Timeline
Apr 1, 2022 → Dec 23, 2022
NCT ID
NCT05296382About Tebipenem tablet form
Tebipenem tablet form is a phase 1 stage product being developed by Spero Therapeutics for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT05296382. Target conditions include Relative Bioavailability.
What happened to similar drugs?
1 of 1 similar drugs in Relative Bioavailability were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05296382 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 23 |
| ABT-333 | AbbVie | Phase 1 | 29 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 29 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 29 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 40 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 23 |